Research progress of inflammatory microenvironment in NF1 related neurofibroma

doi:10.19438/j.cjoms.2021.04.018

Abstract

Abstract: Neurofibroma is one of the characteristic lesions of neurofibromatosis type 1. However, the pathogenesis of neurofibromas is still not completely known. The highly active RAS-GTP signal transduction of Schwann cells with biallelic inactivation can produce a large number of cytokines, which provides a cytokine-rich microenvironment for immune cell recruitment. In normal peripheral nerves, the proportion of immune inflammatory cells is not high. In NF1-related neurofibromas, 30% of the cells are monocytes/macrophages. Mast cells, T cells and dendritic cells (DC) also present. Increased evidences indicate that there is a correlation between inflammation and tumorigenesis. This review summarized the research progress of inflammatory cells in the microenvironment of NF1-related neurofibroma.

Key words: Neurofibromatosis type 1, Neurofibroma, Mast cell, Macrophage, Tumor inflammatory microenvironment

CLC Number:

R739.8

YOU Yuan-he, WANG Yan-an. Research progress of inflammatory microenvironment in NF1 related neurofibroma[J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(4): 376-379.

References

[1] Kallionpää RA, Uusitalo E, Leppävirta J, et al.Prevalence of neurofibromatosis type 1 in the Finnish population[J]. Genet Med, 2018, 20(9): 1082-1086.
[2] Monroe CL, Dahiya S, Gutmann DH.Dissecting clinical heterogeneity in neurofibromatosis type 1[J]. Annu Rev Pathol, 2017, 12(1): 53-74.
[3] Ratner N, Miller SJ.A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor[J]. Nat Rev Cancer, 2015, 15(5): 290-301.
[4] Gutmann DH, Ferner RE, Listernick RH, et al.Neurofibromatosis type 1[J]. Nat Rev Dis Primers, 2017, 3: 17004.
[5] Khu KJ, Midha R.Malignant peripheral nerve sheath tumors[J]. World Neurosurg, 2016, 94(5): 566-567.
[6] Li S, Chen Z, Le LQ.New insights into the neurofibroma tumor cells of origin[J]. Neurooncol Adv, 2020, 2(Suppl 1): i13-i22.
[7] Chen Z, Liu C, Patel AJ, et al.Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma[J]. Cancer Cell, 2014, 26(5): 695-706.
[8] Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease[J]. Cell, 2017, 170(1): 17-33.
[9] Martin GA, Viskochil D, Bollag G, et al.The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21[J]. Cell, 1990, 63(4): 843-849.
[10] Dvorak HF.Tumors: wounds that do not heal-redux[J]. Cancer Immunol Res, 2015, 3(1): 1-11.
[11] Liao CP, Booker RC, Brosseau JP, et al.Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis[J]. J Clin Invest, 2018, 128(7): 2848-2861.
[12] Müller M, Leonhard C, Krauthausen M, et al.On the longevity of resident endoneurial macrophages in the peripheral nervous system: a study of physiological macrophage turnover in bone marrow chimeric mice[J]. J Peripher Nerv Syst, 2010, 15(4): 357-365.
[13] Liao CP, Pradhan S, Chen Z, et al.The role of nerve microenvironment for neurofibroma development[J]. Oncotarget, 2016, 7(38): 61500-61508.
[14] Brosseau JP, Liao CP, Wang Y, et al.NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation[J]. Nat Commun,2018, 9(1): 5014.
[15] Brosseau JP, Le LQ.Heterozygous tumor suppressor microenvironment in cancer development[J]. Trends Cancer, 2019, 5(9): 541-546.
[16] Wernersson S, Pejler G.Mast cell secretory granules: armed for battle[J]. Nat Rev Immunol, 2014, 14(7): 478-494.
[17] Yoshida Y, Adachi K, Yamamoto O.Local mast cell histamine and plasma histamine levels in neurofibromatosis type 1[J]. Acta Derm Venereol, 2010, 90(6): 637-639.
[18] Staser K, Yang FC, Clapp DW.Mast cells and the neurofibroma microenvironment[J]. Blood, 2010, 116(2): 157-164.
[19] Xu J, Zhang H, Li C, et al.Activation of PLCγ/AKT/IκBα/p65 signaling increases inflammation in mast cells to promote growth of cutaneous neurofibroma[J]. Life Sci,2019, 239: 117079.
[20] Lennartsson J, Rönnstrand L.Stem cell factor receptor/c-Kit: from basic science to clinical implications[J]. Physiol Rev, 2012, 92(4): 1619-1649.
[21] Yang C, Chen S, Clegg T, et al.Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling[J]. Hum Mol Genet, 2006, 15(16): 2421-2437.
[22] Robertson KA, Nalepa G, Yang FC, et al.Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial[J]. Lancet Oncol, 2012, 13(12): 1218-1224.
[23] Riccardi VM.A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching[J]. Arch Dermatol, 1993, 129(5): 577-581.
[24] Prada CE, Jousma E, Rizvi TA, et al.Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition[J]. Acta Neuropathol, 2013, 125(1): 159-168.
[25] Stratton JA, Holmes A, Rosin NL, et al. Macrophages regulate schwann cell maturation after nerve injury[J]. Cell Rep, 2018, 24(10): 2561-2572.e6.
[26] Choi K, Komurov K, Fletcher JS, et al.An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system[J]. Sci Rep, 2017, 7: 43315.
[27] Boal LH, Glod J, Spencer M, et al.Pediatric PK/PD phase I trial of pexidartinib in relapsed and refractory leukemias and solid tumors including neurofibromatosis type I-related plexiform neurofibromas[J]. Clin Cancer Res, 2020, 26(23): 6112-6121.
[28] Jia J, Zhang H, Zhang H, et al.Infiltrating Macrophages induced stem-cell-like features through PI3K/AKT/GSK3β signaling to promote neurofibroma growth[J]. Arch Med Res, 2020, 51(2): 124-134.
[29] Fletcher JS, Springer MG, Choi K, et al.STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma[J]. Oncogene, 2019, 38(15): 2876-2884.
[30] Wu J, Liu W, Williams JP, et al.EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation[J]. Oncogene, 2017, 36(12): 1669-1677.
[31] Cortez-Retamozo V, Etzrodt M, Newton A, et al.Origins of tumor-associated macrophages and neutrophils[J]. Proc Natl Acad Sci USA, 2012, 109(7): 2491-2496.
[32] Noy R, Pollard JW.Tumor-associated macrophages: from mechanisms to therapy[J]. Immunity, 2014, 41(1): 49-61.
[33] Haworth KB, Arnold MA, Pierson CR, et al.Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy[J]. Oncotarget, 2017, 8(47): 82037-82048.
[34] Wang S, Liechty B, Patel S, et al.Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors[J]. J Neurooncol, 2018, 138(1): 183-190.
[35] Farschtschi S, Park SJ, Sawitzki B, et al.Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients[J]. Cancer Immunol Immunother, 2016, 65(9): 1113-1121.
[36] Marjanska A, Kubicka M, Kurylo-Rafinska B, et al.Lymphocyte subpopulations in patients with neurofibromatosis type 1-associated optic pathway gliomas and plexiform neurofibromas[J]. Anticancer Res, 2019, 39(11): 6389-6392.
[37] Fletcher JS, Wu J, Jessen WJ, et al.Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice[J]. JCI Insight, 2019, 4(3): e98601.
[38] Van Raemdonck K, Van den Steen PE, Liekens S, et al. CXCR3 ligands in disease and therapy[J]. Cytokine Growth Factor Rev, 2015, 26(3): 311-327.
[39] Brosseau JP, Liao CP, Le LQ.Translating current basic research into future therapies for neurofibromatosis type 1[J]. Br J Cancer, 2020, 123(2): 178-186.